比利时生物科技公司Galapagos NV(GLPG)今日盘前大跌8.04%,报收36.4欧元,引发市场关注。从财报数据来看,这种股价重挫或受到公司最新季度业绩大幅低于市场预期的影响。
在最新公布的2024年第三季度财报中,Galapagos公司调整后每股亏损77美分,远高于分析师此前平均预期的49美分亏损。营收数据也令人失望,同比下滑50.1%至5985万欧元,也低于市场的6944万欧元预期。
值得关注的是,分析师对Galapagos未来盈利的平均预测在过去三个月里下降了约155.7%,反映出外界对该公司前景信心的持续走低。当前投资界给予该股的一致评级为"持有"。显然,本季度业绩疲弱和利润前景堪忧令该公司在投资者心中形象大打折扣,加上资金外流,导致其股价在盘前遭遇重挫。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.